In contrast, the miR-17 miRNA family becomes activated in PKD models, where it appears to mediate Pkd1 repression well into adulthood, as evidenced by the attenuation of cyst growth by the anti-miR-17 drug RGLS4326, even if the treatment is initiated at later stages of the disease. Here, PKD1 is linked to cyst.